Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00229697
Status:
COMPLETED
Last Update Posted:
2015-10-05
First Post:
2005-09-28
Brief Title:
Phase II Metastatic ERPgR Nolvadex - Iressa Study
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Phase II Randomised Double-Blind Stratified Multi-Centre Trial Comparing the Nolvadex 20 Mg And Placebo Combination To The Nolvadex 20 Mg and ZD1839 IRESSA 250 MG Combination In Patients With Metastatic Breast Cancer And Estrogen Receptor ER andor Progesterone PR Positive Tumours
Status:
COMPLETED
Status Verified Date:
2015-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is being carried out to see if ZD1839 is effective in treating metastatic breast cancer in combination with Nolvadex and if so how it compares with Nolvadex alone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| D7917C00225 | None | None | None |